

1 **Distinct T cell functional profiles in SARS-CoV-2 seropositive and seronegative children**
2 **associated with endemic human coronavirus cross-reactivity.**

3
4 Ntombi S. B. Benede^{1,2}, Marius B. Tincho^{1,2}, Avril Walters^{1,2}, Vennesa Subbiah^{1,2}, Amkele
5 Ngomti^{1,2}, Richard Baguma^{1,2}, Claire Butters¹, Mathilda Mennen³, Sango Skelem³,
6 Marguerite Adriaanse³, Strauss van Graan^{4,5}, Sashkia R. Balla^{4,5}, Thandeka Moyo-Gwete^{4,5},
7 Penny L. Moore^{1,4,5,6}, Maresa Botha^{7,8}, Lesley Workman^{7,8}, Heather J. Zar^{1,7,8,9}, Ntobeko A.
8 B. Ntusi^{1,3,9,10}, Liesl Zühlke^{1,7,10,11}, Kate Webb^{11,12}, Catherine Riou^{1,2,9}, Wendy A.
9 Burgers^{1,2,9}, Roanne S. Keeton^{1,2*}

10

11 ¹Institute of Infectious Disease and Molecular Medicine, University of Cape Town,
12 Observatory, South Africa

13 ²Division of Medical Virology, Department of Pathology, University of Cape Town,
14 Observatory, South Africa

15 ³Department of Medicine, University of Cape Town and Groote Schuur Hospital,
16 Observatory, South Africa

17 ⁴National Institute for Communicable Diseases of the National Health Laboratory Services,
18 Johannesburg, South Africa;

19 ⁵MRC Antibody Immunity Research Unit, School of Pathology, University of the
20 Witwatersrand, Johannesburg, South Africa;

21 ⁶Centre for the AIDS Programme of Research in South Africa, Durban, South Africa;

22 ⁷Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South
23 Africa.

24 ⁸Medical Research Council (MRC) Unit on Child and Adolescent Health, University of Cape
25 Town, Cape Town, South Africa

26 ⁹Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,
27 Observatory, South Africa

28 ¹⁰Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Observatory,
29 South Africa.

30 ¹¹South African Medical Research Council, Francie Van Zijl Drive, Parow Cape Town, South
31 Africa

32 ¹²Crick African Network, The Francis Crick Institute, London, United Kingdom.

33 ¹³Division of Paediatric Rheumatology, Department of Paediatrics and Child Health, Red
34 Cross War Memorial Children's Hospital, University of Cape Town, Observatory, South
35 Africa

36

37

38 *Correspondence: Roanne S. Keeton (roanne.keeton@uct.ac.za)

39

40 **SUMMARY** (Word count: 148/150)

41 SARS-CoV-2 infection in children typically results in asymptomatic or mild disease. There is
42 a paucity of studies on antiviral immunity in African children. We investigated SARS-CoV-
43 2-specific T cell responses in 71 unvaccinated asymptomatic South African children who
44 were seropositive or seronegative for SARS-CoV-2. SARS-CoV-2-specific CD4+ T cell
45 responses were detectable in 83% of seropositive and 60% of seronegative children.
46 Although the magnitude of the CD4+ T cell response did not differ significantly between the
47 two groups, their functional profiles were distinct, with SARS-CoV-2 seropositive children
48 exhibiting a higher proportion of polyfunctional T cells compared to their seronegative
49 counterparts. The frequency of SARS-CoV-2-specific CD4+ T cells in seronegative children
50 was associated with the endemic human coronavirus (HCoV) HKU1 IgG response. Overall,
51 the presence of SARS-CoV-2-responding T cells in seronegative children may result from
52 cross-reactivity to endemic coronaviruses and could contribute to the relative protection from
53 disease observed in SARS-CoV-2-infected children.

54

55 **Key words:** SARS-CoV-2, Children, IgG responses, T cell response, Polyfunctional profile,
56 endemic HCoV

57

58 **INTRODUCTION:**

59 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in children
60 usually causes asymptomatic or mild illness, contrasting with the high rate of severe disease
61 reported in older adults ^{1,2}. As a result, global reports of coronavirus disease 2019 (COVID-
62 19) cases among children and adolescents are underreported. The United Nations
63 International Children’s Emergency Fund (UNICEF) estimates that 21% of all reported
64 confirmed cases occur in individuals younger than 20 years ³.

65 In the USA, it has been documented that COVID-19-associated hospitalization rates among
66 children less than 18 years were lower compared to those in older individuals ⁴. Indeed, the
67 COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) reported that
68 children younger than 18 years accounted for only 4.2% of COVID-19-associated
69 hospitalization and 0.2% of COVID-19-associated in-hospital deaths ⁵. In South Africa,
70 during the first 2 years of the pandemic, 12.5% of confirmed cases and 0.7% of COVID-19
71 associated in-hospital deaths were in individuals younger than 19 years ⁶.

72 In contrast to the low COVID-19 severity in the majority of younger individuals, it is known
73 that children are more susceptible than adults to other acute viral respiratory tract infections
74 including respiratory syncytial virus (RSV), rhinovirus (RV), influenza virus and common
75 circulating human coronaviruses (HCoV) ⁷. Several age-associated factors have been
76 proposed to play a role in the reduction of severity to SARS-CoV-2 infection in children ^{2,8},
77 including limited comorbidities ⁹⁻¹¹, differences in the expression of SARS-CoV-2 viral
78 entry factors ¹²⁻¹⁴, robust innate immune responses ¹⁵⁻¹⁸, humoral and cellular immunity ¹⁹⁻²¹
79 and pre-existing immunity against common cold circulating endemic HCoVs ²²⁻²⁶. Endemic
80 HCoVs account for 15 to 30% of respiratory infections reported annually in children ^{27,28}.
81 These HCoVs belong to the alpha-coronavirus subfamily (HCoV-229E and HCoV-NL63)
82 and the beta-coronavirus subfamily (HCoV-OC43 and HCoV-HKU1) and have seasonal
83 infection peaks during the winter season and are responsible for high rates of infection among
84 children ^{29,30}.

85 It is well established that protective immune responses to SARS-CoV-2 encompass both an
86 antibody as and T cell components ³¹. Several studies have reported robust and durable
87 antibody and T cell responses against SARS-CoV-2, which are maintained up to 6-12 months
88 following infection ^{21,32-35}. However, data on T cell responses in children compared to adults
89 are conflicting, with studies reporting lower SARS-CoV-2-specific T cell responses in

90 children ^{23,36,37}, no differences ³⁸ or greater T cell responses in children ²². Many of these
91 studies make use of ELISPOT assays which preclude analysis of T cell phenotypes or
92 functional cytokine profiles.

93 In this study, we prospectively characterized specific T cell responses in SARS-CoV-2
94 seropositive and seronegative children during the COVID pandemic and determined the
95 functional profiles of SARS-CoV-2-specific T cells, in the context of their pre-existing
96 immunity against endemic beta-HCoVs. This study provides novel insights into cross-
97 reactive immunity to SARS-CoV-2 in children.

98 **RESULTS:**

99 **Study cohort**

100 To investigate SARS-CoV-2-specific immune responses, we measured immunoglobulin (Ig)
101 G and T cell responses in 71 children recruited in Cape Town, Western Cape, South Africa.
102 The participants are described in **Figure 1A**. The median age of the children was 7 years
103 (interquartile range (IQR) 2.8-9 years) and 34% (24/71) were female. The children included
104 in this study had not received any SARS-CoV-2 vaccine prior to recruitment and no PCR-
105 confirmed infection data were available, although 58% showed SARS-CoV-2 seropositivity
106 (defined as being positive for either anti-spike or anti-nucleocapsid IgG). Samples were
107 collected between 1 February 2021 – 20 May 2021, after two infection waves in South
108 Africa, that were dominated by the ancestral D614G strain followed by the Beta variant of
109 concern³⁹.

110 **SARS-CoV-2-specific antibody responses in children**

111 To characterize the children serologically, we measured IgG responses against SARS-CoV-2
112 spike (S) and nucleocapsid (N) proteins using an indirect Enzyme-linked immunosorbent
113 assay (ELISA) (**Figure 1B**). A large proportion (58%, 41/71) of unvaccinated children had
114 detectable SARS-CoV-2-specific IgG against spike and/or nucleocapsid proteins and were
115 classified as seropositive. Of the seropositive children, 30% (21/71) had spike- and
116 nucleocapsid-specific IgG, 23% (16/71) had only spike-specific IgG and 5% (4/71) had only
117 nucleocapsid-specific IgG only (**Figure 1B**). The remaining 42% (30/71) had undetectable
118 SARS-CoV-2-spike and nucleocapsid-specific IgG and were classified as seronegative
119 (**Figure 1B**). IgG responses to spike and nucleocapsid are shown for the 41 seropositive
120 children in **Figure 1C**.

121 **SARS-CoV-2-specific T cell responses in children**

122 The magnitude of SARS-CoV-2-specific T cell responses in children was quantified using a
123 whole blood assay and intracellular cytokine staining followed by flow cytometry. SARS-
124 CoV-2-specific CD4⁺ and CD8⁺ T cell responses were measured as total cytokine
125 production of interferon- γ (IFN- γ), tumor necrosis factor- α (TNF- α) or interleukin-2 (IL-2) in
126 response to a combined peptide pool covering SARS-CoV-2 spike (S), nucleocapsid (N) and
127 membrane (M) proteins (**Figure 2A**).

128 We assessed the proportion of responders and magnitude of SARS-CoV-2-specific T cell
129 responses according to the serostatus of the children (**Figure 2B and C**). As expected, 83%
130 (34/41) of seropositive children had detectable SARS-CoV-2-specific CD4⁺ T cells.
131 Interestingly, 60% (18/30) of seronegative children also had detectable SARS-CoV-2-specific
132 CD4⁺ T cells, although this was a significantly lower proportion than observed in the
133 seropositive group ($p=0.0311$). The magnitude of the SARS-CoV-2-specific CD4⁺ T cell
134 response in seronegative responders was comparable to that observed in seropositive children
135 (median of responders: 0.04% and 0.057% respectively; $p=0.437$, **Figure 2B**). Conversely,
136 we did not observe significant differences in the proportion of SARS-CoV-2 CD8⁺ T cell
137 responders (~50%) or the frequency of SARS-CoV-2-specific CD8⁺ T cells between
138 seropositive and seronegative children (median of responders: 0.019% and 0.025%
139 respectively; $p=0.214$, **Figure 2C**).

140 Next, we evaluated the polyfunctional profile of SARS-CoV-2-responding CD4⁺ and CD8⁺
141 T cells based on the co-expression of IFN- γ , IL-2 or TNF- α (**Figure 2D, E**). The overall
142 functional profile of SARS-CoV-2-specific CD4⁺ T cells in seropositive children was distinct
143 from that of seronegative children ($p=0.007$, **Figure 2D**). SARS-CoV-2-specific CD4⁺ T
144 cells in seropositive children were more polyfunctional, exhibiting a higher proportion of
145 triple functional IFN- γ +IL-2+TNF- α +producing CD4⁺ T cells ($p=0.0044$), and dual
146 expressing cells (IL-2+TNF- α +, $p=0.0048$; IFN- γ +IL-2+, $p\leq 0.0001$) compared to the
147 seronegative children. In contrast, seronegative children were characterized by an increased
148 proportion of IFN- γ monofunctional CD4⁺ T cells ($p=0.0048$). Considering the CD8
149 compartment, we detected no significant differences in the overall functional profile of
150 SARS-CoV-2-responding CD8⁺ T cells between the two groups ($p=0.098$), although
151 seropositive children did have a larger proportion of CD8⁺ T cells producing both IFN- γ and
152 IL-2 ($p=0.027$) and single IFN- γ ($p=0.011$) (**Figure 2E**).

153 Taken together, these data show that a significant proportion of seronegative children have
154 detectable SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells. Notably, these CD4⁺ T cells
155 exhibit a distinct polyfunctional profile compared to those found in SARS-CoV-2-exposed
156 children.

157 **Pre-existing immunity to endemic common circulating human coronaviruses**

158 The presence of SARS-CoV-2-responding CD4⁺ T cells primarily exhibiting a
159 monofunctional profile observed in seronegative children led us to hypothesize that the T cell

160 response could be due to cross-reactivity resulting from prior infection with common
161 circulating endemic HCoV-s. Therefore, we measured endemic betacoronavirus HCoV-HKU1
162 and HCoV-OC43 spike IgG in SARS-CoV-2 seropositive and seronegative children. The
163 magnitude of both HCoV-HKU1 (**Figure 3A**) and HCoV-OC43 (**Supplemental Figure 1A**)
164 spike IgG was comparable in the seropositive and seronegative groups (median OD: 0.746 vs
165 0.420; $p=0.153$ for HCoV-HKU1 and 1.769 vs 1.281; $p=0.07$ for HCoV-OC43, respectively).
166 We found a significant correlation between the frequency of SARS-CoV-2-specific CD4+ T
167 cells and HCoV-HKU1-spike IgG in seronegative children ($p=0.036$, $r=0.392$, **Figure 3B**),
168 while no correlation was observed in seropositive children ($p=0.936$, $r=-0.013$, **Figure 3C**).
169 For HCoV-OC43, no correlation was detected in either the seronegative ($p=0.324$, $r=-0.187$,
170 **Supplemental Figure 1B**) or the seropositive group ($p=0.171$, $r=-0.218$, **Supplemental**
171 **Figure 1C**). Overall, these results indicate SARS-CoV-2-reactive CD4+ T cell responses in
172 seronegative children could be due in part to cross-reactive T cell immunity resulting from
173 prior infection with common cold HCoV-HKU1.

174

175 **SARS-CoV-2-specific T cell responses in SARS-CoV-2 seropositive children compared** 176 **to COVID-19 convalescent adults**

177 Blood and plasma samples were collected from 30 COVID-19 convalescent healthcare
178 workers (HCWs) participating in a longitudinal study at Groote Schuur Hospital (Cape Town,
179 Western Cape, South Africa) (**Figure 4A**). All convalescent adults had a prior PCR-
180 confirmed SARS-CoV-2 infection (median 224 days prior to sampling) and had not received
181 a COVID-19 vaccine at the time of sampling. Samples were collected between 22 January
182 2021 – 23 February 2021.

183 A trend towards a higher proportion of SARS-CoV-2 CD4 responders was observed in
184 convalescent adults (97%) compared to seropositive children (83%) ($p=0.07$, **Figure 4B**).
185 Moreover, in SARS-CoV-2 responders, convalescent adults did have a significantly higher
186 frequency of SARS-CoV-2-specific CD4+ T cells compared to seropositive children (median
187 of responders: 0.092% vs 0.057%; $p=0.0004$, respectively). Unlike CD4+ T cell responses,
188 there were no significant differences in either the proportion of CD8 responders (53% vs
189 49%, $p=0.705$) or the frequency of SARS-CoV-2-specific CD8+ T cells (median of
190 responders: 0.038% vs 0.019%; $p=0.096$) between convalescent HCWs and seropositive
191 children (**Figure 4C**). Furthermore, we observed a positive correlation between age and the

192 frequency of SARS-CoV-2-specific CD4+ T cells ($p=0.0006$, $r=0.396$, **Figure 4D**). No
193 correlation was observed with SARS-CoV-2-specific CD8+ T cells and age ($p=0.116$,
194 $r=0.188$, **Figure 4E**). Overall, these results show that convalescent adults mount higher
195 SARS-CoV-2-specific CD4 T cell responses compared to children, which could be attributed
196 to age-related T cell development.

197 **DISCUSSION**

198 T cells have been associated with protection from severe COVID-19⁴⁰. It is therefore
199 important to understand the nature of T cell responses targeting SARS-CoV-2 in children,
200 who have been largely spared from severe COVID-19. In this study, comparing SARS-CoV-
201 2-specific T cell responses in SARS-CoV-2 seropositive and seronegative children, a sizable
202 proportion of seronegative children had SARS-CoV-2-reactive CD4⁺ and CD8⁺ T cells, but
203 their CD4⁺ T cells exhibited a distinct functional profile compared to seropositive children.
204 Importantly, in seronegative children, the frequency of SARS-CoV-2-reactive CD4⁺ T cells
205 positively associated with HCoV-HKU1 spike-specific IgG antibodies. Additionally, we
206 showed that convalescent adults had a higher magnitude of CD4⁺ T cell responses against
207 SARS-CoV-2 compared to seropositive children, which associated positively with age.

208 Our data are in accordance with several studies showing that children develop robust humoral
209 and cellular immunity to SARS-CoV-2^{20,22,38,41,42}. In addition, SARS-CoV-2-specific T cell
210 responses have been detected in 40-60% of SARS-CoV-2 unexposed individuals including
211 children and adults^{22,23,43-48} suggesting possible cross reactivity to HCoVs. One study
212 demonstrated that the proportion of T cell responders was higher in children than adults²². In
213 contrast, a study by Tsang et al. found that SARS-CoV-2 uninfected children failed to mount
214 detectable T cell responses⁴¹. A further study showed that only a small proportion of
215 seronegative children mounted a SARS-CoV-2-specific CD4⁺ T cell response (13%)
216 compared to 60% in seropositive siblings, despite similar exposure in shared households⁴².
217 These two studies differ from our findings, where we showed that 60% of seronegative
218 children had detectable SARS-CoV-2-specific T cell responses, consistent with Dowell et al
219²². The discrepancies between the studies could be due to a difference in the seasonal
220 prevalence of circulating HCoVs in each study setting^{29,30,49}, different T cell assays used to
221 analyze T cell responses, and/or the cohort demographics.

222 Although the source of SARS-CoV-2 reactive T cells in seronegative children remains
223 unclear, mounting evidence argues for cross-reactivity to endemic HCoVs. HCoVs (including
224 beta HCoVs-HKU1 and OC43, and alpha HCoVs-NL63 and 229E) have partial sequence
225 homology with SARS-CoV-2^{44,50}. While cross reactive humoral responses have been shown
226 not to underly this protection⁵¹, studies have reported pre-existing T cell responses to
227 endemic HCoVs with cross-reactivity to SARS-CoV-2 in unexposed adults^{47,52-57} and
228 children^{22,24,58,59}. These cellular responses were targeted mainly towards the S2 subunit

229 which is highly conserved among coronaviruses ^{22,25}. In our study, we showed a positive
230 correlation between the frequency of SARS-CoV-2 CD4+ T cells and the magnitude of
231 HKU1 spike-specific IgG in SARS-CoV-2 seronegative children. Our findings are supported
232 by similar findings showing that 58% (7/12) seronegative children had binding antibodies
233 against alpha and/or beta HCoV spike proteins, which they concluded were likely due to
234 recent HCoV infection ²².

235 Pre-existing immunity from endemic HCoVs infection or exposure has been shown to be
236 associated with a protective effect against COVID-19 disease in adults ^{53,56,57,60,61}. Sagar et al.
237 showed that individuals with a documented recent or ongoing HCoV infection and SARS-
238 CoV-2 infection had fewer COVID-19-associated complications when hospitalized,
239 compared to individuals without HCoV infection ⁶⁰. Previously, the clinical relevance of pre-
240 existing immunity and cross-reactive cellular responses in providing protection from
241 infection in children was unclear. Recently however, Dowell et al. demonstrated that as for
242 SARS-CoV-2 seropositive children, SARS-CoV-2-reactive T cell responses in SARS-CoV-2
243 seronegative children were protective against Omicron infection, suggesting a protective role
244 in SARS-CoV-2 unexposed individuals ⁶².

245 Polyfunctional T cells have been reported to be associated with protection against a number
246 of viral diseases ⁶³⁻⁶⁶. These include protection against cytomegalovirus (CMV) infection
247 after lung transplantation ⁶⁴, improved viral control of hepatitis C virus (HCV) ⁶⁵ and
248 detection during human immunodeficiency virus (HIV) infection in long term non-
249 progressors ⁶⁶. We found that seropositive children had a more polyfunctional profile of
250 SARS-CoV-2-specific CD4+ T cells while CD4 responses in seronegative children exhibited
251 a predominantly monofunctional profile. The SARS-CoV-2-specific polyfunctional Th1 CD4
252 response (characterized by co-expression of IFN- γ , TNF- α and/or IL-2), as seen in
253 seropositive children, may be necessary for effective viral control and has been documented
254 in COVID-19 convalescent adults ^{67,68}.

255 The distinct functional profiles reported in our findings could be a result of differing degrees
256 memory cell T cell differentiation or low SARS-CoV-2 peptide binding affinity with HCoV-
257 specific T cells resulting in low T cell activation. The affinity between MHC molecules
258 presenting peptide and the T cell receptor (TCR) plays a role in antigen recognition. It has
259 been proposed that T cells with high affinity TCRs have greater effector functions and
260 therefore an increased polyfunctional profile compared to low affinity TCRs ^{69,70}. TCR cross-

261 recognition of peptides on MHCs that are not structurally identical results in lower binding
262 affinity which decreases T cell polyfunctionality^{70,71}. It is therefore plausible that the
263 monofunctional profile of SARS-CoV-2 CD4+ T cell responses in seronegative children
264 observed in our study may be mediated by cross-recognition of pre-existing T cell immunity
265 to HCoV-HKU1, where partial sequence homology between HCoV-HKU1 and SARS-CoV-2
266 results in low peptide binding affinity and a different functional T cell profile^{44,55,69,71,72}. It is
267 noteworthy to report that we did not find any association with the other beta HCoV-OC43
268 spike-specific IgG and SARS-CoV-2-specific T cells in seronegative children, which could
269 be related to differences in seasonal prevalence of types of HCoV infections.

270 Numerous studies have now compared the magnitude of the SARS-CoV-2 specific T cell
271 response in children to those detectable in adults^{22,23,36–38,41}. Initially it was thought that
272 children may have a higher magnitude of T cell responses given their relative resistance to
273 severe disease and the link between T cell responses and protection from severe disease^{8,73}.
274 However, children were shown to have lower T cell responses than adults in most studies,
275 including the current study^{23,36,37}. A plausible explanation is that adults have a mature
276 immune system with more differentiated memory T cell subsets endowed with increased
277 cytokine capacity, whereas children have an immature immune system, with many more
278 naïve T cells which have reduced cytokine producing capacity, are enriched for
279 monofunctional responses and have increased antigen dependence⁷⁴. Despite lower
280 circulating SARS-CoV-2-specific T cells, children and adults may also have different
281 responses in the respiratory tract. There is evidence in adults demonstrating the presence of
282 SARS-CoV-2-specific T cell responses in the nasal mucosa after infection and vaccination
283^{75,76}. However comparative studies have yet to be performed in children. Additionally, several
284 studies have proposed that one potential contributing factor to age-related COVID-19 clinical
285 outcome are the robust innate immune responses observed in children, which may contribute
286 to early control of viral replication^{15–17,77}. Recent studies have shown that, compared to
287 adults, SARS-CoV-2 seronegative children exhibited an increased number of innate immune
288 cells with pre-activated signatures leading to early production of interferon-mediated antiviral
289 effects in the upper respiratory tract^{18,19}.

290 In conclusion, our study shows that a robust SARS-CoV-2-specific T cell response is
291 observed in children, including in those with no evidence of prior SARS-CoV-2 infection.
292 We demonstrate that the magnitude of SARS-CoV-2-reactive CD4+ T cells in seronegative
293 children correlates with HCoV-HKU1 exposure. This, together with a distinct functional

294 profile of SARS-CoV-2-specific responding CD4+ T cells observed between seropositive and
295 seronegative children provides further evidence for pre-existing T cell responses cross-
296 reactive to SARS-CoV-2.

297 **Limitations of the study**

298 This study relied on serology to determine SARS-CoV-2 exposure. With no PCR
299 confirmation of SARS-CoV-2 infection, the exact time of infection of the children could not
300 be determined. Additionally, our study investigated T cell responses against SARS-CoV-2
301 spike, nucleocapsid and membrane proteins, and not the non-structural viral proteins that can
302 also serve as targets for the T cell response, thus not capturing the full extent of T cell
303 reactivity in infected participants. Furthermore, we did not address durability of the T cell
304 responses in children due to the cross-sectional design of the study.

305

306

307

308

309

310

311

312

313

314

315

316

317

318 **METHODS:**

319 **Lead contact**

320 Further information and requests for resources and reagents should be directed to and will be
321 fulfilled by the lead contact: Roanne S. Keeton (roanne.keeton@uct.ac.za).

322

323 **Materials availability**

324 Materials will be made available by request to Roanne S. Keeton (roanne.keeton@uct.ac.za).

325

326 **Data and code availability**

327 The published article includes all data generated or analyzed during this study, and
328 summarized in the accompanying tables, figures, and supplemental materials.

329

330 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

331 **Study participants**

332 Paediatric participants (n=71) were recruited from two cohorts in the Western Cape, South
333 Africa. The first cohort enrolled 50 children from the Red Cross War Memorial Children's
334 Hospital (Cape Town, Western Cape, South Africa). In this cohort 50/71 children were
335 hospitalized for non-COVID-19-related elective procedures. A further 21 children were
336 enrolled from the Drakenstein Child Health Study (DCHS) (Cape Winelands Western Cape,
337 South Africa), a birth cohort study⁷⁸. The participants from this study were recruited between
338 1 February 2021 and 20 May 2021, after the first and the second infection waves with
339 Ancestral strain and Beta variant in South Africa⁷⁹. Parents or legal guardians provided
340 written informed consent for all paediatric participants. For the DCHS longitudinal cohort,
341 this was renewed annually. The study was approved by the University of Cape Town Human
342 Research Ethics Committee (HREC 599/2020 for the RC cohort and HREC 401/2009 for the
343 DCHS cohort).

344 COVID-19 convalescent unvaccinated adults from a longitudinal study of healthcare workers
345 (HCW) enrolled from Groote Schuur Hospital (Cape Town, Western Cape, South Africa)

346 were included in the study (n=30). HCW in this cohort were recruited between July 2020 and
347 January 2021 and were selected for inclusion based on a prior PCR-confirmed SARS-CoV-2
348 infection at least 3 months earlier. All participants were asymptomatic or had mild symptoms
349 and did not require hospitalization for COVID-19 and were symptom-free at the time of
350 sampling. Written informed consent was obtained from all participants and the study was
351 approved by the University of Cape Town Human Research Ethics Committee (HREC
352 190/2020 and 209/2020).

353

354 **METHODS DETAILS**

355 **SARS-CoV-2 and HCoV antigens**

356 For serology assays, recombinant SARS-CoV-2 spike S1 (Cape Bio Pharms), and SARS-
357 CoV-2 nucleocapsid (BioTech Africa) proteins were used for this study.

358 HKU1 and OC43 spike proteins were expressed in Human Embryonic Kidney (HEK) 293F
359 suspension cells by transfecting the cells with the spike plasmid. After 6 days, proteins were
360 purified using a nickel resin followed by size-exclusion chromatography. Relevant fractions
361 were collected and frozen at -80°C until use.

362 SARS-CoV-2 peptides used for T cell assays included a commercially available peptide pool
363 (15mers peptides with 11 amino acid overlap) covering the immunodominant regions of
364 SARS-CoV-2 spike protein (PepTivator SARS-CoV-2 Prot_S, Miltenyi Biotech) based on
365 the Wuhan-1 strain. The Spike peptide pool was prepared by resuspending in distilled water
366 and used at a final concentration of 1 µg/ml. SARS-CoV-2 (Wuhan-1) nucleocapsid and
367 membrane peptides (17mers with 10 amino acid overlap spanning the full proteins) were
368 obtained from BEI Resources and were prepared by resuspending in dimethyl sulfoxide
369 (DMSO, Sigma) and used at a concentration of 1 µg/ml.

370 **Enzyme-linked immunosorbent assay (ELISA)**

371 SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA) was performed to
372 characterize the serostatus of participants, as previously described⁸⁰. Two µg/ml of spike
373 protein was used to coat 96-well high-binding plates and incubated overnight at 4 °C. The
374 plates were incubated in a blocking buffer consisting of 1% casein, 0.05% Tween 20, 1x
375 Phosphate-Buffered Saline (PBS) for SARS-CoV-2 or 1x PBS, 5% skimmed milk powder,

376 0.05% Tween 20 for HCoV. Plasma samples were diluted to 1:50 for SARS-CoV-2 or 1:100
377 for HCoVs in the respective blocking buffer. For the SARS-CoV-2 ELISA, secondary
378 antibody was diluted to 1:5000 in dilution buffer and added to the plates followed by
379 SigmaFast O-phenylenediamine dihydrochloride (OPD) substrate. For the HCoV ELISAs,
380 secondary antibody was diluted to 1:3000 in blocking buffer and added to the plates followed
381 by TMB substrate (ThermoFisher Scientific). Upon stopping the reaction with 1-3 M sulfuric
382 acid, absorbance was measured at a wavelength of 490 nm for SARS-CoV-2 or 450 nm for
383 HCoVs. A cut-off for positivity was set at two standard deviations (SD) above the mean
384 optical density (OD) of prepandemic samples for SARS-CoV-2 ELISAs

385 **Whole blood-based T cell assay**

386 Blood was collected in sodium heparin tubes and processed within 4-6 hours of collection.
387 The whole blood assay sample processing used for this study was adapted from a whole
388 blood intracellular cytokine detection assay designed to detect SARS-CoV-2 specific T cells
389 in adults^{81,82}. Briefly, 500 µl of blood was stimulated for 24 hours at 37°C with a combined
390 pool of SARS-CoV-2 peptides including S, N and M, all at 1 µg/mL in the presence of
391 costimulatory antibodies against CD28 (clone 28.2) and CD49d (clone L25) (1 µg/mL each;
392 BD Biosciences) and Brefeldin A (10 µg/mL, Sigma-Aldrich). Unstimulated blood was
393 incubated with costimulatory antibodies, Brefeldin A and an equimolar amount of DMSO as
394 a background control. After 24 hours, blood was treated with EDTA (2 mM) for 15 minutes
395 followed by red blood cell lysis and white cell fixation using FACS lysing solution (BD
396 Biosciences) for 10 minutes. Cells were then cryopreserved in freezing media (90% fetal
397 bovine serum (FBS) and 10% DMSO) and stored at -80°C until batched analysis.

398 **Cell staining and flow cytometry**

399 Cell staining was performed on cryopreserved fixed cells that were thawed and washed with
400 1% FACS washing buffer (1% FBS in PBS). Cells were stained with the following surface
401 antibody markers: CD4 ECD (SFC112T4D11, Beckman Coulter), CD8 BV510 (RPA-8,
402 Biolegend) and incubated at room temperature for 20 minutes. Cells were permeabilized and
403 stained with intracellular antibody markers CD3 BV650 (OKT3), IFN-γ AlexaFluor® 700
404 (B27), TNF-α BV786 (Mab11) and IL-2 APC (MQ1-17H12) (all from Biolegend). Finally,
405 cells were washed and fixed with Cellfix (BD Biosciences). Samples were acquired on a
406 multiparameter BD Fortessa flow cytometer using Diva software version 8 and analyzed
407 using FlowJo v10. Results are expressed as the frequency of CD4+ or CD8+ T cells

408 expressing IFN- γ , TNF- α or IL-2. Cytokine responses presented are background subtracted
409 values (from the frequency of cytokine produced by unstimulated cells).

410

411 **QUANTIFICATION AND STATISTICAL ANALYSIS**

412 Statistical analyses were performed in Prism (v9.4.1; GraphPad Software Inc, San Diego,
413 CA, USA). Non-parametric tests were used for all comparisons. The Mann-Whitney and
414 Wilcoxon signed rank tests were used for unmatched and paired samples, respectively. Chi-
415 square tests were used for comparisons between the proportion of responders represented as
416 pie charts. All correlations reported are non-parametric Spearman's correlations. Analysis of
417 cytokine co-expressing populations was performed using SPICE version 5.1. *P* values less
418 than 0.05 were considered statistically significant. Details of analyses performed for each
419 experiment are described in the figure legends.

420

421 **ACKNOWLEDGEMENTS**

422 We thank the study participants and the parents/guardians of the children and the clinical staff
423 and personnel at Red Cross War Memorial Children's Hospital, the Drakenstein Child Health
424 Study in Paarl, Western Cape and at Groote Schuur Hospital, Cape Town for their
425 participation. We acknowledge Guarav Kwatra and Shabir Madhi for providing plasmids
426 used for the endemic ELISA proteins. BEI resources provided the following reagents NIAID,
427 NIH: Peptide Array, SARS-Related Coronavirus 2 Nucleocapsid (N) Protein, NR-52404 and
428 SARS-Related Coronavirus 2 Membrane (M) Protein, NR-52403. This work is supported by
429 the South African Medical Research Council (SA-MRC) with funds received from the South
430 African Department of Science and Innovation (DSI), (grants 96825, SHIPNCD 76756, and
431 DST/CON 0250/2012), the Poliomyelitis Research Foundation (21/65) and the Wellcome
432 Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by
433 core funding from the Wellcome Trust (203135/Z/16/Z and 222754). SA-MRC to R.S.K. UK
434 NIHR GECO award (GEC111 to H.J.Z), the Bill & Melinda Gates Foundation, USA (grants
435 OPP1017641, OPP1017579 to H.J.Z). P.L.M. is supported by the South African Research
436 Chairs Initiative of the Department of Science and Innovation and National Research
437 Foundation of South Africa (NRF 9834), the SA Medical Research Council SHIP programme
438 and the Centre for the AIDS Programme of Research in South Africa (CAPRISA). C.R. is

439 supported by the EDCTP2 program of the European Union's Horizon 2020 programme
440 (TMA2017SF-1951-TB-SPEC), the Wellcome Trust (226137/Z/22/Z) and the National
441 Institutes of Health (NIH) (R21AI148027). W.A.B. is supported by the EDCTP2 program of
442 the European Union's Horizon 2020 programme (TMA2016SF-1535-CaTCH-22), the
443 Wellcome Trust (226137/Z/22/Z) and the EU-Africa Concerted Action on SARS-CoV-2
444 Virus Variant and Immunological Surveillance (COVICIS), funded through the EU's
445 Horizon Europe Research and Innovation Programme (101046041). H.J.Z is supported by the
446 SA-MRC. LZ is funded by the South African Medical Research Council (SAMRC) through
447 its Division of Research Capacity Development under the Mid-Career Scientist Programme
448 from funding received from the South African National Treasury. The content hereof is the
449 sole responsibility of the authors and do not necessarily represent the official views of the
450 SAMRC. LJ Zühlke also receives support from the National Research Foundation of South
451 Africa (NRFSA), as well as the UK Medical Research Council (MRC) and the UK
452 Department for International Development (DFID) under the MRC/DFID Concordat
453 agreement, via the African Research Leader Award (MR/S005242/1).

454

455 **AUTHOR CONTRIBUTIONS**

456 R.S.K., K.W. and W.A.B. conceived the study and designed the experiments. N.S.B.B., A.N.
457 and R.B. performed T cell assays. M.B.T., V.S. and A.W. performed SARS-CoV-2 ELISAs.
458 S.V.G. and S.R.B. performed HCoV ELISAs. N.S.B.B., T.M.G., P.L.M., C.R., W.A.B. and
459 R.S.K. analyzed the data. K.W., L.Z., and C.B. established and led the Red Cross childrens
460 cohort. H.J.Z. established and led the Drakenstein Child Health cohort including a COVID
461 sub-study. M.B and L.W. managed the Drakenstein Child Health cohort and repository.
462 N.A.B.N. established and led the adult HCW cohort and M.M., S.S. and M.A. recruited
463 participants and managed the cohort. N.S.B.B., C.R., W.A.B. and R.S.K. wrote the paper. All
464 authors reviewed and edited the manuscript.

465

466 **DECLARATION OF INTERESTS**

467 The authors have no competing interests.

468

469 **FIGURE LEGENDS**

470 **Figure 1: SARS-CoV-2-specific antibody responses in children**

471 (A) The demographic characteristics of 71 unvaccinated children included in this study. Age,
472 gender, SARS-CoV-2 vaccination status, SARS-CoV-2 serology and collection date are
473 shown.

474 (B) Proportion of children exhibiting antibody responses to SARS-CoV-2 spike (S) and
475 nucleocapsid (N) proteins.

476 (C) The magnitude of SARS-CoV-2 S and N IgG antibodies (OD_{490nm}) measured by ELISA
477 in seropositive children (n=41). The dotted lines indicate the cut-off for positivity which was
478 calculated as the mean optical density of COVID-19 prepandemic control samples. Statistical
479 analysis was performed using the Wilcoxon signed rank test; p values <0.05 were considered
480 statistically significant and are bolded.

481

482 **Figure 2: SARS-CoV-2-specific T cell responses in children**

483 (A) Representative flow cytometry plots of SARS-CoV-2-specific interferon- γ (IFN- γ), tumor
484 necrosis factor- α (TNF- α) and interleukin-2 (IL-2) cytokine production from CD4+ (left) and
485 CD8+ (right) T cells in response to SARS-CoV-2 peptide stimulation. NS: no stimulation,
486 SNM: combined peptide pool of SARS-CoV-2-spike, nucleocapsid and membrane proteins.

487 (B) Frequency of SARS-CoV-2-specific CD4+ T cells producing any of the measured
488 cytokines (IFN- γ , IL-2 or TNF- α). Children were grouped according to SARS-CoV-2
489 serostatus (light blue: n=41 SARS-CoV-2 seropositive; dark blue: n=30 SARS-CoV-2
490 seronegative). Bars represent the median of the responders, and median values are indicated.
491 The pie charts represent the proportion of responders with detectable T cell response to
492 SARS-CoV-2 SNM peptides.

493 (C) Frequency of SARS-CoV-2-specific CD8+ T cells producing any of the measured
494 cytokines (IFN- γ , IL-2 or TNF- α). Children were grouped according to SARS-CoV-2
495 serostatus (light red: n=41 SARS-CoV-2 seropositive children; dark red: n=30 SARS-CoV-2
496 seronegative children). Statistical comparisons in (B) and (C) were performed using the
497 Mann-Whitney test between seropositive and seronegative children and the Chi-square test to

498 compare the percentage of responders; p values <0.05 were considered statistically significant
499 and are bolded.

500 (D) Polyfunctional profile of SARS-CoV-2-specific CD4⁺ and (E) CD8⁺ T cells in
501 seropositive and seronegative unvaccinated children. The x-axis illustrates each combination
502 which is indicated with a black circle for the presence of IFN- γ , IL-2 and TNF- α . The
503 medians and interquartile range are shown. Each response pattern (any possible combination
504 of IFN- γ , IL-2 and TNF- α production) is color coded and summarized in the pie charts, with
505 each pie slice representing the median contribution of each combination to the total SARS-
506 CoV-2 responses. The permutation test was used to compare the statistical differences
507 between the pie charts and the Mann Whitney Sum Test to compare response patterns
508 between seropositive and seronegative children; p values <0.05 were considered statistically
509 significant and are bolded.

510 **Figure 3: SARS-CoV-2 cross-reactivity to endemic beta-HCoV in children**

511 (A) The magnitude of HCoV-HKU-1 spike IgG levels were measured by ELISA in SARS-
512 CoV-2 seropositive (light blue; n=41) and seronegative (dark blue; n=29) children. Plasma
513 sample was insufficient for one seronegative child therefore OD for HCoV-HKU1 was not
514 measured for this participant. The bars represent the median values. A statistical comparison
515 was performed using the Mann-Whitney test between seropositive and seronegative children;
516 a p value <0.05 was considered statistically significant.

517 (B) Correlation between the frequency of SARS-CoV-2-specific CD4⁺ T cells and HCoV-
518 HKU-1-spike IgG levels in SARS-CoV-2 seronegative children (n=29). One participant had
519 insufficient sample available to be included in this assay.

520 (C) Correlation between the frequency of SARS-CoV-2-specific CD4⁺ T cells and HCoV-
521 HKU-1-spike IgG levels in SARS-CoV-2 seropositive children (n=41). Statistical
522 comparisons for (B) and (C) were performed using a two-tailed non-parametric Spearman
523 rank tests; p values <0.05 were considered statistically significant and are bolded and
524 correlation coefficients values are shown.

525

526

527 **Figure 4: SARS-CoV-2-specific T cell responses in children compared to convalescent**
528 **adults**

529 (A) The demographic characteristics of 30 unvaccinated convalescent adults included in this
530 study. Age, sex, SARS-CoV-2 PCR-positivity, days since PCR test and collection date are
531 shown.

532 (B) Frequency of SARS-CoV-2-specific CD4⁺ T cells producing any of the measured
533 cytokines (IFN- γ , TNF- α , or IL-2) in SARS-CoV-2 convalescent HCW (purple; n=30) and
534 seropositive children (light blue; n=41). The pie charts represent the proportion of responders
535 with a detectable T cell response to SARS-CoV-2 SNM combined peptide pools. Bars
536 represent median of the responders.

537 (C) Frequency of SARS-CoV-2-specific CD8⁺ T cells producing any of the measured
538 cytokines (IFN- γ , TNF- α , or IL-2) in SARS-CoV-2 convalescent HCW (dark red; n=30) and
539 seropositive children (light red; n=41). The bars represent the median of the responders and
540 median values are indicated. Statistical comparisons were performed using the Mann-
541 Whitney test between seropositive children and adults and the Chi-square test was used to
542 compare the percentage of responders; p values <0.05 were considered statistically significant
543 and are bolded.

544 (D) Correlations between SARS-CoV-2-specific CD4⁺ or CD8⁺ T cells and age in
545 convalescent HCW (purple and dark red; n=30) and seropositive (light blue and light red;
546 n=41) children. Statistical comparisons were performed using a two-tailed non-parametric
547 Spearman rank tests; p values <0.05 were considered statistically significant and are bolded
548 and correlation coefficients are shown.

549

550

551

552

553

554

555

556 **REFERENCES**

- 557 1. Aleebrahim-Dehkordi E, Soveyzi F, Deravi N, Rabbani Z, Saghadzadeh A, Rezaei N.
558 Human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in children. *J*
559 *Pediatr Nurs*. 2021;56:70-79. doi:10.1016/j.pedn.2020.10.020
- 560 2. Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in
561 children. *Nat Immunol*. 2022;23(2):177-185. doi:10.1038/s41590-021-01123-9
- 562 3. UNICEF. COVID-19 confirmed cases and deaths, age and sex-disaggregated data.
563 Published April 2023. [https://data.unicef.org/resources/covid-19-confirmed-cases-](https://data.unicef.org/resources/covid-19-confirmed-cases-and-deaths-dashboard/)
564 [and-deaths-dashboard/](https://data.unicef.org/resources/covid-19-confirmed-cases-and-deaths-dashboard/). Accessed April 27, 2023.
- 565 4. Kim L, Whitaker M, Kambhampati A, et al. Hospitalization Rates and Characteristics
566 of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 —
567 COVID-NET, 14 States, March 1–July 25, 2020. 2020;69(32):1081-1088.
568 <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose->
- 569 5. COVID-NET. COVID-19-Associated Hospitalization Surveillance Network, Centers
570 for Disease Control and Prevention. Published April 2023.
571 https://gis.cdc.gov/grasp/covidnet/covid19_5.html. Accessed April 27, 2023
- 572 6. NICD. *National Institute for Communicable Disease Monthly COVID-19 in*
573 *Children.*; 2022. [https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-](https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/monthly-covid-19-in-children/)
574 [19/surveillance-reports/monthly-covid-19-in-children/](https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/monthly-covid-19-in-children/). Accessed April 27, 2023
- 575 7. Nair H, Brooks A, Katz M, et al. Global burden of respiratory infections due to
576 seasonal influenza in young children: a systematic review and meta-analysis. *The*
577 *Lancet*. 2011;378:1917-1930. doi:10.1016/S0140
- 578 8. Bogunovic D, Merad M. Children and SARS-CoV-2. *Cell Host Microbe*.
579 2021;29(7):1040-1042. doi:10.1016/j.chom.2021.06.015
- 580 9. Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 severe
581 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and
582 adolescents: a systematic review of critically unwell children and the association with
583 underlying comorbidities. *Eur J Pediatr*. 2021;180(10):3251-3252.
584 doi:10.1007/s00431-021-04036-9
- 585 10. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 Infection and Pediatric
586 Comorbidities: A Systematic Review and Meta-Analysis. *International Journal of*
587 *Infectious Diseases*. 2021;103:246-256. doi:10.1016/j.ijid.2020.11.163
- 588 11. Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of
589 COVID-19 in hospital patients age 18-29 years. *PLoS One*. 2021;16(7):1-22.
590 doi:10.1371/journal.pone.0255544
- 591 12. Koch CM, Prigge AD, Anekalla KR, et al. Age-related Differences in the Nasal
592 Mucosal Immune Response to SARS-CoV-2. *Am J Respir Cell Mol Biol*.
593 2022;66(2):206-222. doi:10.1165/rcmb.2021-0292OC

- 594 13. Muus C, Luecken MD, Eraslan G, et al. Single-cell meta-analysis of SARS-CoV-2
595 entry genes across tissues and demographics. *Nat Med.* 2021;27(3):546-559.
596 doi:10.1038/s41591-020-01227-z
- 597 14. Schuler BA, Habermann AC, Plosa EJ, et al. Age-determined expression of priming
598 protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. *J Clin*
599 *Investig.* 2021;131(1):1-7. doi:10.1172/JCI140766
- 600 15. Pierce CA, Sy S, Galen B, et al. Natural mucosal barriers and COVID-19 in children.
601 *JCI Insight.* 2021;6(9):1-10. doi:10.1172/jci.insight.148694
- 602 16. Neeland MR, Bannister S, Clifford V, et al. Innate cell profiles during the acute and
603 convalescent phase of SARS-CoV-2 infection in children. *Nat Commun.*
604 2021;12(1):1-5. doi:10.1038/s41467-021-21414-x
- 605 17. Speranza E. Children primed and ready for SARS-CoV-2. *Nat Microbiol.*
606 2021;6(11):1337-1338. doi:10.1038/s41564-021-00984-y
- 607 18. Loske J, Röhm J, Lukassen S, et al. Pre-activated antiviral innate immunity in the
608 upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol.*
609 2022;40(3):319-324. doi:10.1038/s41587-021-01037-9
- 610 19. Yoshida M, Worlock KB, Huang N, et al. Local and systemic responses to SARS-
611 CoV-2 infection in children and adults. *Nature.* 2021;602(7896):321-327.
612 doi:10.1038/s41586-021-04345-x
- 613 20. Cotugno N, Ruggiero A, Bonfante F, et al. Virological and immunological features of
614 SARS-CoV-2-infected children who develop neutralizing antibodies. *Cell Rep.*
615 2021;34(11):1-e5. doi:10.1016/j.celrep.2021.108852
- 616 21. Méndez-Echevarría A, Sainz T, Falces-Romero I, et al. Long-Term Persistence of
617 Anti-SARS-CoV-2 Antibodies in a Pediatric Population. *Pathogens.* 2021;10(6):1-7.
618 doi:10.3390/pathogens10060700
- 619 22. Dowell AC, Butler MS, Jinks E, et al. Children develop robust and sustained cross-
620 reactive spike-specific immune responses to SARS-CoV-2 infection. *Nat Immunol.*
621 2022;23(1):40-49. doi:10.1038/s41590-021-01089-8
- 622 23. Cohen CA, Li APY, Hachim A, et al. SARS-CoV-2 specific T cell responses are
623 lower in children and increase with age and time after infection. *Nat Commun.*
624 2021;12(1):1-14. doi:10.1038/s41467-021-24938-4
- 625 24. Humbert M, Olofsson A, Wullimann D, et al. Functional SARS-CoV-2 cross-reactive
626 CD4 + T cells established in early childhood decline with age. *Proc Natl Acad Sci.*
627 2023;120(12):1-12. doi:10.1073/pnas.2220320120
- 628 25. Woudenberg T, Pelleau S, Anna F, et al. Humoral immunity to SARS-CoV-2 and
629 seasonal coronaviruses in children and adults in north-eastern France. *EBioMedicine.*
630 2021;70:1-10. doi:10.1016/j.ebiom.2021.103495
- 631 26. Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR.
632 Epidemiology of Seasonal Coronaviruses: Establishing the Context for the Emergence

- 633 of Coronavirus Disease 2019. *J Infect Dis*. 2020;222(1):17-25.
634 doi:10.1093/infdis/jiaa185
- 635 27. Zimmermann C, Curtis N. Coronavirus Infections in Children Including COVID-19.
636 *Pediatr Infect Dis J*. 2020;39(5):355-368. doi:10.1097/INF.0000000000002660
- 637 28. Fehr R A PS. Coronaviruses: An Overview of Their Replication and Pathogenesis.
638 *Methods Mol Biol*. 2015;1282:1-23. doi:10.1007/978-1-4939-2438-7_1.
- 639 29. Park S, Lee Y, Michelow IC, Choe YJ. Global Seasonality of Human Coronaviruses:
640 A Systematic Review. *Open Forum Infect Dis*. 2020;7(11):1-7.
641 doi:10.1093/ofid/ofaa443
- 642 30. Audi A, Allbrahim M, Kaddoura M, Hijazi G, Yassine HM, Zaraket H. Seasonality of
643 Respiratory Viral Infections: Will COVID-19 Follow Suit? *Front Public Health*.
644 2020;8:1-8. doi:10.3389/fpubh.2020.567184
- 645 31. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*.
646 2021;184(4):861-880. doi:10.1016/j.cell.2021.01.007
- 647 32. Garrido C, Hurst JH, Lorang CG, et al. Asymptomatic or mild symptomatic SARS-
648 CoV-2 infection elicits durable neutralizing antibody responses in children and
649 adolescents. *JCI Insight*. 2021;6(17):1-13. doi:10.1172/jci.insight.150909
- 650 33. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed
651 for up to 8 months after infection. *Science*. 2021;371(6529):1-23.
652 doi:10.1126/science.abf4063
- 653 34. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses
654 1 year after infection in people recovered from COVID-19: a longitudinal cohort
655 study. *Lancet Microbe*. 2022;3(5):e348-e356. doi:10.1016/S2666-5247(22)00036-2
- 656 35. Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is
657 maintained at 6 months following primary infection. *Nat Immunol*. 2021;22(5):620-
658 626. doi:10.1038/s41590-021-00902-8
- 659 36. Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2
660 infection in hospitalized pediatric and adult patients. *Sci Transl Med*. 2020;12(564):1-
661 11. doi:10.1126/scitranslmed.abe8120
- 662 37. Kaaijk P, Pimentel VO, Emmelot ME, et al. Children and Adults With Mild COVID-
663 19: Dynamics of the Memory T Cell Response up to 10 Months. *Front Immunol*.
664 2022;13:1-15. doi:10.3389/fimmu.2022.817876
- 665 38. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three
666 children of parents with symptomatic COVID-19. *Nat Commun*. 2020;11(1):1-8.
667 doi:10.1038/s41467-020-19545-8
- 668 39. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of
669 concern in South Africa. *Nature*. 2021;592(7854):438-443. doi:10.1038/s41586-021-
670 03402-9

- 671 40. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol.*
672 2022;23(2):186-193. doi:10.1038/s41590-021-01122-w
- 673 41. Tsang HW, Chua GT, To KKW, et al. Assessment of SARS-CoV-2 Immunity in
674 Convalescent Children and Adolescents. *Front Immunol.* 2021;12:1-10.
675 doi:10.3389/fimmu.2021.797919
- 676 42. Paul K, Sibbertsen F, Weiskopf D, et al. Specific CD4+ T Cell Responses to
677 Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to
678 Beta Variant. *Front Immunol.* 2022;13:1-12. doi:10.3389/fimmu.2022.867577
- 679 43. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-
680 CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
681 *Cell.* 2020;181(7):1489-1501. doi:10.1016/j.cell.2020.05.015
- 682 44. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell
683 epitopes in unexposed humans. *Science.* 2020;370(6512):89-94.
684 doi:10.1126/science.abd3871
- 685 45. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in
686 cases of COVID-19 and SARS, and uninfected controls. *Nature.* 2020;584(7821):457-
687 462. doi:10.1038/s41586-020-2550-z
- 688 46. Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells
689 expand in abortive seronegative SARS-CoV-2. *Nature.* 2021;601(7891):110-117.
690 doi:10.1038/s41586-021-04186-8
- 691 47. Tan HX, Lee WS, Wragg KM, et al. Adaptive immunity to human coronaviruses is
692 widespread but low in magnitude. *Clin Transl Immunology.* 2021;10(3):1-15.
693 doi:10.1002/cti2.1264
- 694 48. Singh V, Obregon-Perko V, Lapp SA, et al. Limited induction of SARS-CoV-2–
695 specific T cell responses in children with multisystem inflammatory syndrome
696 compared with COVID-19. *JCI Insight.* 2022;7(4):1-13.
697 doi:10.1172/jci.insight.155145
- 698 49. Shah MM, Winn A, Dahl RM, Kniss KL, Silk BJ, Killerby ME. Seasonality of
699 Common Human Coronaviruses, United States, 2014-2021. *Emerg Infect Dis.*
700 2022;28(10):1970-1976. doi:10.3201/eid2810.220396
- 701 50. de Vries RD. SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-
702 reactive memory cells does not equal protective immunity. *Signal Transduct Target*
703 *Ther.* 2020;5(1):1-2. doi:10.1038/s41392-020-00338-w
- 704 51. Zar HJ, Nicol MP, MacGinty R, et al. Antibodies to seasonal coronaviruses rarely
705 cross-react with SARS-CoV-2: findings from an African birth cohort. *Pediatr Infect*
706 *Dis J.* 2021;40(12):e516-e519. doi:10.1097/INF.0000000000003325
- 707 52. Da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-Cell Reactivity to
708 Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. *J*
709 *Infect Dis.* 2021;224(1):70-80. doi:10.1093/infdis/jiab176

- 710 53. Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN.
711 Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. *J*
712 *Clin Investig*. 2020;130(12):6631-6638. doi:10.1172/JCI143120
- 713 54. Loyal L, Braun J, Henze L, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2
714 immune responses upon infection and vaccination. *Science*. 2021;374(6564):1-11.
715 doi:10.1126/science.abh1823
- 716 55. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define
717 heterologous and COVID-19-induced T cell recognition. *Nat Immunol*.
718 2021;22(1):74-85. doi:10.1038/s41590-020-00808-x
- 719 56. Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with
720 protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun*.
721 2022;13(1):1-8. doi:10.1038/s41467-021-27674-x
- 722 57. Yu ED, Narowski TM, Wang E, et al. Immunological memory to common cold
723 coronaviruses assessed longitudinally over a three-year period pre-COVID19
724 pandemic. *Cell Host Microbe*. 2022;30(9):1269-1278.
725 doi:10.1016/j.chom.2022.07.012
- 726 58. Saletti G, Gerlach T, Jansen JM, et al. Older adults lack SARS CoV-2 cross-reactive
727 T lymphocytes directed to human coronaviruses OC43 and NL63. *Sci Rep*.
728 2020;10(1):1-10. doi:10.1038/s41598-020-78506-9
- 729 59. Niessl J, Sekine T, Lange J, et al. Identification of resident memory CD8 + T cells
730 with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid
731 tissue. *Sci Immunol*. 2021;6(64):1-11. doi: 10.1126/sciimmunol.abk0894
- 732 60. Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is
733 associated with less-severe COVID-19. *J Clin Investig*. 2021;131(1):1-5.
734 doi:10.1172/JCI143380
- 735 61. Da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-Cell Reactivity to
736 Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. *J*
737 *Infect Dis*. 2021;224(1):70-80. doi:10.1093/infdis/jiab176
- 738 62. Dowell AC, Ireland G, Zuo J, Moss P, Ladhani S. Association of Spike-Specific T
739 Cells with Relative Protection from Subsequent SARS-CoV-2 Omicron Infection in
740 Young Children. *JAMA Pediatr*. 2022;177(1):96-97.
741 doi:10.1001/jamapediatrics.2022.3868
- 742 63. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection:
743 Implications for vaccine design. *Nat Rev Immunol*. 2008;8(4):247-258.
744 doi:10.1038/nri2274
- 745 64. Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict
746 protection from cytomegalovirus after lung transplantation. *Am J Respir Crit Care*
747 *Med*. 2016;193(1):78-85. doi:10.1164/rccm.201504-0733OC


- 748 65. Ciuffreda D, Comte D, Cavassini M, et al. Polyfunctional HCV-specific T-cell
749 responses are associated with effective control of HCV replication. *Eur J Immunol.*
750 2008;38(10):2665-2677. doi:10.1002/eji.200838336
- 751 66. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain
752 highly functional HIV-specific CD8+ T cells. *Blood.* 2006;107(12):4781-4789.
753 doi:10.1182/blood-2005-12-4818
- 754 67. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function,
755 durability, and role in protection. *Sci Immunol.* 2020;5(49):1-5.
756 doi:10.1126/sciimmunol.abd6160
- 757 68. Bertoletti A, Le Bert N, Tan AT. SARS-CoV-2-specific T cells in the changing
758 landscape of the COVID-19 pandemic. *Immunity.* 2022;55(10):1764-1778.
759 doi:10.1016/j.immuni.2022.08.008
- 760 69. Spear TT, Evavold BD, Baker BM, Nishimura MI. Understanding TCR affinity,
761 antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for
762 cancer immunotherapy. *Cancer Immunol, Immunother.* 2019;68(11):1881-1889.
763 doi:10.1007/s00262-019-02401-0
- 764 70. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics:
765 impact on T-cell activity and specificity. *Immunology.* 2009;126(2):165-176.
766 doi:10.1111/j.1365-2567.2008.03015.x
- 767 71. Tan MP, Gerry AB, Brewer JE, et al. T cell receptor binding affinity governs the
768 functional profile of cancer-specific CD8+ T cells. *Clin Exp Immunol.*
769 2015;180(2):255-270. doi:10.1111/cei.12570
- 770 72. Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19.
771 *Immunity.* 2021;54(1):14-18. doi:10.1016/j.immuni.2020.12.009
- 772 73. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive
773 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and
774 Disease Severity. *Cell.* 2020;183(4):996-1012.e19. doi:10.1016/j.cell.2020.09.038
- 775 74. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell
776 differentiation: Human memory T-cell subsets. *Eur J Immunol.* 2013;43(11):2797-
777 2809. doi:10.1002/eji.201343751
- 778 75. Ssemaganda A, Nguyen HM, Nuhu F, et al. Expansion of cytotoxic tissue-resident
779 CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following
780 mRNA COVID-19 vaccination. *Nat Commun.* 2022;13(1):1-9. doi:10.1038/s41467-
781 022-30913-4
- 782 76. Lim JME, Tan AT, Bert N Le, Hang SK, Low JGH, Bertoletti A. SARS-CoV-2
783 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and
784 CD4+ T cells of broad specificity. *J Exp Med.* 2022;219(10):1-10.
785 doi:10.1084/jem.20220780
- 786 77. Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory
787 syndromes associated with SARS-cov-2 infection: Dysregulation of the immune

- 788 response across the age spectrum. *J Clin Investig.* 2020;130(12):6194-6197.
789 doi:10.1172/JCI145301
- 790 78. Zar HJ, Barnett W, Myer L, Stein DJ, Nicol MP. Investigating the early-life
791 determinants of illness in Africa: the Drakenstein Child Health Study. *Thorax.*
792 2015;70(6):592-594. doi:10.1136/thoraxjnl-2014-206242
- 793 79. Zar HJ, MacGinty R, Workman L, et al. Natural and hybrid immunity following four
794 COVID-19 waves: A prospective cohort study of mothers in South Africa.
795 *EClinicalMedicine.* 2022;53:1-12. doi:10.1016/j.eclinm.2022.101655
- 796 80. Makatsa MS, Tincho MB, Wendoh JM, et al. SARS-CoV-2 Antigens Expressed in
797 Plants Detect Antibody Responses in COVID-19 Patients. *Front Plant Sci.* 2021;12:1-
798 13. doi:10.3389/fpls.2021.589940
- 799 81. Mutavhatsindi H, Riou C. Protocol to quantify and phenotype SARS-CoV-2-specific
800 T cell response using a rapid flow-cytometry-based whole blood assay. *STAR Protoc.*
801 2022;3(4):1-15. doi:10.1016/j.xpro.2022.101771
- 802 82. Riou C, Schäfer G, du Bruyn E, et al. Rapid, simplified whole blood-based
803 multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. *Eur*
804 *Respir.* 2022;59(1):1-13. doi:10.1183/13993003.00285-2021
- 805
- 806
- 807 Click or tap here to enter text.


A


	Children
N	71
Age (median, IQR)	7 (2.8 - 9)
Gender (n, % female)	24 (34%)
SARS-CoV-2 vaccination (n, %)	0 (0%)
SARS-CoV-2 seropositive (n, %)	41 (58%)
Sample collection date	1 February 2021 – 20 May 2021


B All children (n=71)



C SARS-CoV-2 seropositive children (n=41)









A

	Convalescent adults
N	30
Age (median, IQR)	37.5 (32.3 - 45.3)
Gender (n, % female)	22 (73%)
SARS-CoV-2 PCR positivity (n, %)	30 (100%)
Days since PCR+ (median, IQR)	224 (189 - 239)
Sample collection date	22 January 2021 - 23 February 2021

B



C



D

